Aligos Therapeutics, Inc. (ALGS) financial statements and ratios from SEC XBRL: revenue $2.19M (TTM), net margin -1106.7%, revenue growth -39.5% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $2.19M |
| Net Margin | -1106.7% |
| Revenue Growth (YoY) | -39.5% |
| EPS Growth (YoY) | -88.3% |
| Price / Book | 1.29 |
| Price / Sales | 6.41 |
| Altman Z-Score | -11.87 (distress) |
| Sector P/E (Healthcare) | 21.7 |
ALGS overview · ALGS earnings · ALGS KPIs · ALGS investor relations · ALGS ownership · ALGS peers · ALGS filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.